ADC Therapeutics at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
ADC Therapeutics exhibits at Booth 2529 at ASH 2026 in New Orleans. Its presence centres on non-Hodgkin lymphoma, supporting a symposium that answers community oncologists' questions about novel therapies. It also supports one on how biomarkers and drug mechanisms are reshaping management of diffuse large B-cell lymphoma.
| Organization | ASH 2026 Attendance |
|---|---|
ADC Therapeutics Lausanne, Switzerland | |
Antibody-drug conjugate developer that markets loncastuximab tesirine (Zynlonta) for relapsed or refractory diffuse large B-cell lymphoma. | Booth Exhibiting at Booth 2529 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know: A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Redefining DLBCL — How Biomarker- and Mechanism-Driven Strategies Are Reshaping Management Across the Disease Continuum Using molecular subtypes of diffuse large B-cell lymphoma to choose frontline treatment among polatuzumab regimens, bispecific antibodies, and CAR-T. |
Instantly find 20 buyers from ADC Therapeutics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction